Dual Antiplatelet Therapy for 3 or 12 Months in Patients with Non-ST-elevation MI/Unstable Angina or ST-elevation MI: Analysis of the REDUCE Trial
Journal of Asian Pacific Society of Cardiology · 2022
DOI: 10.15420/japsc.2021.29 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Asian Pacific Society of Cardiology, 2022. Verfasst von Wan Azman Wan Ahmad und 12 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The aim of this subanalysis of the REDUCE (Short-term Dual Antiplatelet Therapy in Patients with ACS Treated with the COMBO Dual-therapy Stent) trial was to evaluate differences between non-ST-elevation MI/unstable angina (NSTEMI/UA) patients and ST-elevation MI (STEMI) patients in terms of patient characteristics, procedures and outcomes.
Methods
In the REDUCE trial, 1,496 acute coronary syndrome patients undergoing successful COMBO stent implantation were randomised to 3 or 12 months of dual antiplatelet therapy (DAPT) treatment. In total, 789 (52.8%) patients had NSTEMI/UA and 706 (47.2%) had STEMI. For this analysis, NSTEMI/UA patients (n=789) were compared with STEMI patients (n=706).
Results
In the analysis of the NSTEMI/UA and STEMI cohorts comparing 3-month DAPT (751 patients) and 12-month DAPT treatment (745 patients) there were no statistically significant differences in the primary endpoints of all-cause mortality, MI, stent thrombosis, stroke, target vessel revascularisation or bleeding (Bleeding Academic Research Consortium [BARC] II, III, V) at 360 and 720 days between the two cohorts. Comparing the overall primary endpoints in the NSTEMI/UA cohort, 3-month DAPT was better than 12-month DAPT (9.6% versus 10.0% at 360 days and 12.1% versus 15.0% at 720 days). In the STEMI cohort, 12-month DAPT was better than 3-month DAPT (8.4% versus 11.0% at 720 days).
Conclusion
For NSTEMI/UA patients, a numerically lower occurrence of outcomes was observed with 3-month DAPT at 360 and 720 days, whereas for STEMI patients, 12-month DAPT appeared to be better at 720 days. NSTEMI patients seemed to have less favourable long-term outcomes than STEMI patients in this subanalysis. Further adequately powered randomised trials are needed to confirm the findings.
Zitieren
APA
Ahmad, W. A. W., Benit, E., Legrand, V. M., Yahya, A. F., Tan, H. C., Rifqi, S., Kader, M. A. S. A., Pironi, B., Winter, R. J. D., Tam, C. F., Ligtenberg, E., Luca, G. D., & Suryapranata, H. (2022). Dual Antiplatelet Therapy for 3 or 12 Months in Patients with Non-ST-elevation MI/Unstable Angina or ST-elevation MI: Analysis of the REDUCE Trial. Journal of Asian Pacific Society of Cardiology. https://doi.org/10.15420/japsc.2021.29
Vancouver
Ahmad WAW, Benit E, Legrand VM, Yahya AF, Tan HC, Rifqi S, et al. Dual Antiplatelet Therapy for 3 or 12 Months in Patients with Non-ST-elevation MI/Unstable Angina or ST-elevation MI: Analysis of the REDUCE Trial. Journal of Asian Pacific Society of Cardiology. 2022. doi:10.15420/japsc.2021.29
BibTeX
@article{Ahmad2022,
author = {Ahmad, Wan Azman Wan and Benit, Edouard and Legrand, Victor M and Yahya, Achmad Fauzi and Tan, Huay Cheem and Rifqi, Sodiqur and Kader, Muhamad Ali SK Abdul and Pironi, Bruno and Winter, Robert J de and Tam, Chor-Cheung Frankie and Ligtenberg, Eric and Luca, Giuseppe De and Suryapranata, Harry},
title = {Dual Antiplatelet Therapy for 3 or 12 Months in Patients with Non-ST-elevation MI/Unstable Angina or ST-elevation MI: Analysis of the REDUCE Trial},
journal = {Journal of Asian Pacific Society of Cardiology},
year = {2022},
doi = {10.15420/japsc.2021.29}
}
EUVIMED